Genetic Technologies Ltd (ASX:GTG; Nasdaq:GENE) is the most active stock intra-day with over 113 million shares changing hands, although its value has eased 10.5% to $0.017.
The company has regained compliance with Nasdaq Marketplace following a deficiency notice in mid-2017.
Genetic Technologies is a molecular diagnostics company that offers cancer predictive testing and assessment tools to help physicians proactively manage patient health.
The company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.
Adding interest and following a strategic review, the company remains in active discussions with multiple parties regarding a potential transaction.
Further details will be closely monitored by investors.
Company Name | Code | Last | Change | Volume |
---|---|---|---|---|
Genetic Technologies Ltd | GTG | $0.017 | -10.53% | 113,744,014 |
Pancontinental Oil & Gas NL | PCL | $0.005 | 0% | 95,747,144 |
Queensland Bauxite Ltd | QBL | $0.069 | -8% | 71,822,947 |
Bard1 Life Sciences Ltd | BD1 | $0.016 | 33.33% | 64,333,658 |
Atlas Iron Ltd | AGO | $0.032 | -3.03% | 64,299,962 |
Ardiden Ltd | ADV | $0.023 | 15% | 61,450,080 |
Serpentine Technologies Ltd | S3R | $0.017 | 21.43% | 49,188,225 |
Fatfish Internet Group Ltd | FFG | $0.100 | 21.95% | 36,935,922 |
Kairos Minerals Ltd | KAI | $0.055 | 14.58% | 32,602,587 |
Lepidico Ltd | LPD | $0.067 | 6.35% | 27,529,056 |